We are live on ! Find out more
LPCN icon

Lipocine
LPCN

49 hedge funds and large institutions have $4.16M invested in Lipocine in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,133% more call options, than puts

Call options by funds: $471K | Put options by funds: $9K

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

7% more funds holding

Funds holding: 46 → 49 (+3)

0.02% less ownership

Funds ownership: 0.72% → 0.7% (-0.02%)

14% less capital invested

Capital invested by funds: $4.85M → $4.16M (-$694K)

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

Holders
49
Holders Change
+3
Holders Change %
+6.52%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
11
Closed
4
Calls
$471K
Puts
$9K
Net Calls
+$462K
Net Calls Change
-$18K

Top Buyers

1
B
Bailard
California
+$35.6K
2
WP
Wealthspan Partners
Iowa
+$31.7K
3
TSS
Two Sigma Securities
New York
+$7.2K
4
UBS Group
UBS Group
Switzerland
+$4.7K
5
TRCT
Tower Research Capital (TRC)
New York
+$4.14K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$80.9K
2
VF
Virtu Financial
New York
-$42K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$20.2K
4
WE
Wealth Effects
Massachusetts
-$15.9K
5
Two Sigma Investments
Two Sigma Investments
New York
-$15.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.51M +$860 +118 +0.1%
BlackRock
2
BlackRock
New York
$581K +$2.62K +359 +0.4%
WE
3
Wealth Effects
Massachusetts
$469K -$15.9K -2,177 -3%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$318K -$867 -119 -0.2%
BCM
5
Bridgeway Capital Management
Texas
$163K – – –
State Street
6
State Street
Massachusetts
$122K – – –
Two Sigma Investments
7
Two Sigma Investments
New York
$115K -$15.4K -2,110 -11%
KAS
8
Kestra Advisory Services
Texas
$113K +$3.27K +448 +3%
Renaissance Technologies
9
Renaissance Technologies
New York
$78K -$1.33K -182 -2%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$71K – – –
Two Sigma Advisers
11
Two Sigma Advisers
New York
$64.6K -$20.2K -2,770 -22%
Northern Trust
12
Northern Trust
Illinois
$63.9K – – –
Mercer Global Advisors
13
Mercer Global Advisors
Colorado
$63K – – –
Citadel Advisors
14
Citadel Advisors
Florida
$40.9K -$80.9K -11,107 -64%
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$32K – – –
B
16
Bailard
California
$31.9K +$35.6K +4,880 New
MML Investors Services
17
MML Investors Services
Massachusetts
$31K – – –
WP
18
Wealthspan Partners
Iowa
$29.4K +$31.7K +4,350 New
CL
19
Choreo LLC
Illinois
$25K – – –
LPL Financial
20
LPL Financial
California
$24.5K -$532 -73 -2%
Millennium Management
21
Millennium Management
New York
$24K -$4.82K -661 -15%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$21.1K – – –
Charles Schwab
23
Charles Schwab
California
$19.2K – – –
Ameriprise
24
Ameriprise
Minnesota
$18K +$51 +7 +0.3%
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$14.7K +$860 +118 +6%
1
2 3

LPCN Hedge Fund Activity: Q4 2022 in Review

49 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2022, worth a combined $4.16M — down 14% from $4.85M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new LPCN positions and 4 closed out — a net gain of 3 holders — while 8 added to existing stakes and 11 trimmed.

The largest buyer was Bailard, opening a new position worth an estimated $35.6K. The largest seller was Citadel Advisors, cutting an estimated $80.9K.

  • 49 institutional investors held Lipocine (LPCN) as of Q4 2022, up from 46 in Q3 2022.
  • Funds reported $4.16M of Lipocine stock for Q4 2022, down 14% quarter-over-quarter.
  • 7 funds opened new Lipocine positions in Q4 2022 and 4 closed out, a net change of +3 holders.
  • The largest Lipocine buyer in Q4 2022 was Bailard, an estimated $35.6K added.
  • The largest Lipocine seller in Q4 2022 was Citadel Advisors, an estimated $80.9K sold.

Based on aggregated 13F filings for Q4 2022.